.jpg)
TLR Agonist Nano Immune Therapy Clears Peritoneal and Systemic Ovarian Cancer (Adv. Healthcare Mater. 7/2025)
Advanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
Pathogen Mimetic Particles
In article 2402966, Rita E. Serda and co-workers show endocytosis of Toll-like receptor (TLR) agonist-modified mesoporous silica particles by peritoneal myeloid cells. Activation of surface and endosomal TLRs activates myeloid cells, enhancing anti-cancer immunity. Art by Lorél Medina.
